Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells. It is available in oral (delayed-release tablets, suspension) and intravenous formulations.
## Primary Indications
* Short-term treatment of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Prophylaxis of stress-related mucosal bleeding (IV formulation).
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg PO or IV once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg PO daily.
* **Hypersecretory Conditions:** Starting dose 40 mg PO twice daily; titrate up to 240 mg/day if clinically indicated.
* **Stress Ulcer Prophylaxis:** 40 mg IV once daily.
## Pediatric Dosing
* **GERD (5 years and older):**
* 15 kg to <40 kg: 20 mg PO once daily.
* ≥40 kg: 40 mg PO once daily.
* **Duration:** Typically limited to 8 weeks in pediatric populations.
## Dose Adjustments
* **Hepatic Impairment:** No specific dose adjustment defined for mild-to-moderate impairment, but clinical monitoring is advised. In severe impairment, use caution; consider dose reduction or every-other-day dosing.
* **Renal Impairment:** No dosage adjustment necessary.
## Contraindications
* Known hypersensitivity to pantoprazole or any substituted benzimidazole (e.g., omeprazole, lansoprazole).
* Concomitant use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, cutaneous/systemic lupus erythematosus, and bone fractures.
## Key Drug Interactions
* **pH-Dependent Absorption:** May decrease absorption of drugs like atazanavir, ketoconazole, and mycophenolate mofetil.
* **Methotrexate:** Potential for increased methotrexate levels, particularly at high doses (toxicity risk).
* **CYP2C19/3A4:** While less than other PPIs, monitor for levels of drugs with narrow therapeutic indices (e.g., warfarin).
* **Clopidogrel:** Interaction significance is debated, but avoidance is often suggested if possible.
## Monitoring
* **Baseline/Intermittent:** Serum magnesium (for long-term therapy), vitamin B12 (if on long-term therapy), and renal function (suspected interstitial nephritis).
* **Long-term:** Monitor for fracture risk factors and gastrointestinal symptoms indicating relapse.
## Clinical Pearls
* **Administration:** Tablets should be swallowed whole; do not crush or chew. IV formulation must be reconstituted and administered as a slow injection or infusion to prevent phlebitis.
* **Deprescribing:** Utilize "tapering" strategies (e.g., every other day dosing or PRN use) to prevent rebound hypersecretion upon discontinuation of chronic therapy.
* **Local Protocol:** Institutional requirements for stress ulcer prophylaxis (SUP) vary significantly. Always verify if the patient meets high-risk criteria for SUP before ordering prophylaxis.
***
*Disclaimer: This information is for educational purposes and does not replace professional medical judgment or institutional policy. Always consult the most current prescribing information (package insert) and your facility's drug formulary before prescribing or administering medication.*
